After pricing its once-obscure drug, Acthar, in the stratosphere, Questcor gained many fans on Wall Street. But the company has also drawn some doubters.

Source: http://www.nytimes.com/2012/12/30/business/questcor-finds-profit-for-acthar-drug-at-28000-a-vial.html?partner=rss&emc=rss

This entry was posted on Sunday, December 30th, 2012 at 6:50 pm and is filed under Technology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.